MG
RCKT icon

Michael Gelband’s Rocket Pharmaceuticals RCKT Stock Holding History

Michael Gelband’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.7K Sell
18,635
-76,545
-80% -$255K ﹤0.01% 1477
2026
Q1 		$341K Sell
95,180
-83,746
-47% -$333K ﹤0.01% 1282
2025
Q4 		$628K Sell
178,926
-63,258
-26% -$217K ﹤0.01% 1133
2025
Q3 		$790K Buy
242,184
+77,147
+47% +$243K 0.01% 1042
2025
Q2 		$404K Sell
165,037
-35,647
-18% -$181K ﹤0.01% 1197
2025
Q1 		$1.34M Buy
200,684
+10,805
+6% +$107K 0.01% 835
2024
Q4 		$2.39M Buy
189,879
+124,261
+189% +$1.87M 0.02% 659
2024
Q3 		$1.21M Buy
+65,618
New +$1.34M 0.01% 917
2023
Q3 		– Sell
-34,798
Closed -$691K – 2060
2023
Q2 		$691K Sell
34,798
-271,264
-89% -$5.48M 0.01% 1237
2023
Q1 		$5.24M Buy
+306,062
New +$5.99M 0.04% 497
2022
Q4 		– Sell
-37,402
Closed -$597K – 2043
2022
Q3 		$597K Buy
37,402
+19,727
+112% +$308K 0.01% 1301
2022
Q2 		$243K Sell
17,675
-2,819
-14% -$33.6K ﹤0.01% 1605
2022
Q1 		$325K Buy
+20,494
New +$354K ﹤0.01% 1730
2021
Q1 		– Sell
-36,085
Closed -$1.98M – 2515
2020
Q4 		$1.98M Buy
36,085
+6,516
+22% +$238K 0.02% 546
2020
Q3 		$676K Buy
+29,569
New +$729K 0.01% 861
2020
Q1 		– Sell
-31,054
Closed -$707K – 1544
2019
Q4 		$707K Buy
31,054
+18,454
+146% +$308K 0.01% 690
2019
Q3 		$147K Buy
+12,600
New +$156K 0.01% 1188

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Michael Gelband's RCKT Position: Q2 2026 in Review

Michael Gelband reduced its Rocket Pharmaceuticals (RCKT) stake by 80% in Q2 2026, selling an estimated $255K and leaving 18,635 shares worth $63.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1477.

Michael Gelband first reported a position in RCKT in Q3 2019 and has held it in 17 quarters since. The position peaked at $5.24M in Q1 2023. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Michael Gelband held 18,635 shares of Rocket Pharmaceuticals worth $63.7K as of Q2 2026.
  • Michael Gelband sold 76,545 Rocket Pharmaceuticals shares in Q2 2026, an estimated $255K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1477 holding.
  • Michael Gelband first reported a position in Rocket Pharmaceuticals in Q3 2019 and has held it in 17 quarters since.
  • Michael Gelband's Rocket Pharmaceuticals position peaked at $5.24M in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.